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Many diagnostic and therapeutic concepts require antibodies of high specificity. Recombinant binder
libraries and related selection approaches allow the efficient isolation of antibodies against almost every
target of interest. Nevertheless, it cannot be guaranteed that selected antibodies perform well and
interact specifically enough with analytes unless an elaborate characterisation is performed. Here, we
present an approach to shorten this process by combining the selection of suitable antibodies with the
identification of informative target molecules by means of antibody microarrays, thereby reducing the
effort of antibody characterisation by concentrating on relevant molecules. In a pilot scheme, a library of
456 single-chain variable fragment (scFv) binders to 134 antigens was used. They were arranged in a
microarray format and incubated with the protein content of clinical tissue samples isolated from
pancreatic ductal adenocarcinoma and healthy pancreas, as well as recurrent and non-recurrent bladder
tumours. We observed significant variation in the expression of the E3 ubiquitin-protein ligase (CHFR) as
well as the glutamate receptor interacting protein 2 (GRIP2), for example, always with more than one of
the scFvs binding to these targets. Only the relevant antibodies were then characterised further on
antigen microarrays and by surface plasmon resonance experiments so as to select the most specific and
highest affinity antibodies. These binders were in turn used to confirm a microarray result by
immunohistochemistry analysis.Introduction
The demand for highly specific and high-affinity antibodies is
continuously and rapidly growing [1]. The advances in genomicCorresponding author: Hoheisel, J.D. (j.hoheisel@dkfz.de)
www.elsevier.com/locate/nbt 
574 1871-6784/ 2015 The Authors. Published by Elsevier B.sequencing, for example, are uncovering more and more disease-
related changes, which frequently need to be elucidated in pro-
tein-based assays since they exhibit their functional effect at this
molecular level. Companion diagnostics, in which the application
of a drug is directly coupled to a patient stratification process, ishttp://dx.doi.org/10.1016/j.nbt.2015.12.003
V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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eralso of increasing importance. Since most drugs affect proteins,
most assays will probably analyse this molecular class, too. Access
to antibodies is crucial for such ends. Currently, the antibody field
is still dominated by monoclonal antibodies isolated from hybrid-
oma cells [2]. While they represent the gold standard at present,
binders that originate from recombinant selection systems are
catching up quickly and are expected to become the norm sooner
rather than later [3,4]. Based on libraries that can match the
antibody diversity of the human immune system, they allow
the isolation of binders to almost any desired target. They also
permit flexibility with respect to the actual application profile.
Binders against linear epitopes, for example, may not be suitable
for recognition of three-dimensional structures and vice versa. By
adaptation of the selection parameters, antibodies from a single
library can meet varying requirements. However, similar to anti-
bodies from hybridomas, the production of recombinant binders
faces the common problem that individual molecules resulting
from the initial selection screens differ tremendously in quality, in
particular with respect to specificity and affinity. The majority of
generated molecules will eventually fail quality requirements at
some stage, making the effort already invested on characterisation
useless and void.
In an effort to shorten the usually successively executed pro-
cesses of antibody production, characterisation, application for
antigen identification and selection of binders that exhibit appro-
priate performance parameters and are of informative value, we
propose to combine the last three steps, at least partially, by means
of binder microarrays. After an initial selection process – panning
from a library by removing the antibodies that do not bind the
targeted antigens at all – the remaining antibodies will be arrayed
and incubated with protein samples of interest. For lack of any
extensive characterisation, a large percentage of the primary anti-
body hits will be identified immediately as being of inadequate
quality. At the same time, however, molecules will be found that
exhibit at least some degree of specificity and yield reproducible
results that could be of biological or biomedical relevance. Only
antibodies that meet sufficiently both requirements – binding
specificity and informative value – will be characterised further
in order to determine their quality. Once quality is established, the
antibodies can then be used to confirm in other analysis formats
the biological finding made in the microarray experiment.
In a pilot experiment, we have investigated a set of 456 recom-
binant antibodies. They were made within the framework of the
Affinomics consortium, the most recent of three European net-
works for binder production and characterisation [5], and were
designed to bind 134 tumour-associated antigens. Instead of
selecting the best candidates in a one-by-one analysis of specificity
and affinity, they were arranged as an antibody microarray with-
out knowing about their quality. By incubation with clinical
protein samples, we could combine the identification of proteins,
which exhibit differential expression, with an identification of
related antibodies with apparently appropriate performance.
These antibodies were then subjected to further characterisation.
Molecules that passed the process were subsequently used to
validate the original microarray result by immunohistochemistry.
In the analysis, protein extracts from pancreatic and bladder
cancer were used as well as appropriate controls. Pancreatic cancer
is currently the most lethal cancer entity in the Western world [6].Most patients die within a year of diagnosis, with mean survival
being about five months; mortality is basically identical to
incidence. In comparison, bladder cancer is far less lethal and
frequently diagnosed relatively early. Low-stage, non muscle-
invasive bladder cancer can usually be resected successfully. How-
ever, 60% of the tumours recur and then often become invasive [7].
Materials and methods
Antibody microarray production
The antibodies were part of the human single-chain variable
fragment (scFv) gene libraries HAL4/7/8 [8] and HAL9/10 [9].
Initial selections against 134 antigens (132 proteins and 2 pep-
tides; Supplementary Tab. 1) of oncological context and poor
coverage by commercial monoclonal antibodies were performed
by library panning as described [10] leading to a set of 456 scFvs.
Concentration dependent binding to the respective target mole-
cules was confirmed by an ELISA using dilution series of the
antibodies. The scFvs were then re-cloned so as to link them to
a human IgG1 Fc part as described in detail [8]. The fusion proteins
have superior stability. Experimentally, they behave very similarly
to IgG antibodies and can be used with them in immunoassays
without changing the underlying protocols. The antibodies were
expressed in HEK293 6E cells and purified by affinity chromatog-
raphy on protein A [11]. Antibody microarrays were prepared as
described in detail previously [12,13]. In brief, the antibodies were
spotted onto epoxysilane-coated slides (25 mm  75 mm, Nexter-
ion-E; Schott, Jena, Germany) using the contact printer MicroGrid
II 610 (Apogent Discoveries, Mittenwald, Germany) and SMP6B
pins (Telechem, Sunnyvale, USA) at a humidity of 55–65%. The
printing buffer was composed of 50 mM sodium bicarbonate, pH
9.0, 100 mM NaCl, 50 mM MgCl2, 0.005% (w/v) sodium azide,
0.25% (w/v) dextran, 0.006% (w/v) Igepal CA-630 (Sigma–Aldrich,
St. Louis, USA) and 1 mg/ml of the respective antibody. All anti-
bodies were spotted in quadruplicate on each microarray slide. The
spots featured a diameter of about 250 mm. After the actual print-
ing process, the slides were allowed to equilibrate at room temper-
ature and 55–65% humidity overnight. They were then stored in
dry and dark conditions at 48C.
Preparation of protein samples
For all tissue samples, written informed consent was obtained from
the patients or donors. The analyses performed were approved by
the local ethics committee. As a matter of fact, tumour specimens
were used, which had been studied before in a different setting. The
bladder cancer samples had been isolated from patients with and
without tumour recurrence after five years [14]. Also, we used nine
tissue samples of patients with pancreatic adenocarcinoma (PDAC)
and seven pancreas samples of patients, who had no cancer but had
their pancreas removed for other reasons [15; unpublished results].
The protein extracts had been prepared as described in detail
previously [13]. Total protein concentration was measured by the
BCA assay (Thermo Fisher Scientific, Waltham, USA) and adjusted to
1 mg/ml. The protein was labelled with 0.4 mg/ml of the NHS-ester
of the fluorescent dye Dy-549 (Dyomics, Jena, Germany) in 100 mM
sodium bicarbonate buffer, pH 8.5, 1% (w/v) Triton-100 on a shaker
at 48C. After 1 h, the reaction was stopped by addition of 10%
glycine. Unreacted dye was removed 30 min later and the buffer
changed to phosphate-buffered saline (PBS) using Zeba Desaltwww.elsevier.com/locate/nbt 575
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is possible [16], it is not used routinely. Variations in labelling
efficiency are normalised during the data analysis process. Subse-
quently, the Complete Protease Inhibitor Cocktail (Roche, Man-
nheim, Germany) was added as recommended by the manufacturer.
All labelled protein samples were stored in aliquots at 208C until
use. For competitive dual-colour incubation [17], a common refer-
ence sample was produced by pooling identical amounts of all
protein samples and labelling the pool with the dye Dy-649 (Dyo-
mics). The same reference sample was used throughout the analyses.
Antibody microarray analysis
Surface blocking and sample incubation were performed using a
Tecan HS 4800 hybridisation system (Tecan, Ma¨nnedorf,
Switzerland). Slides were blocked with the Candor Blocking Solu-
tion (Candor Biosciences, Wangen, Germany) for 1 h and incu-
bated with labelled protein for 3 h. Subsequently, the slides were
scanned with a Tecan Powerscanner and images were analysed
using GenePix 6.0 microarray analysis software (Axon Instru-
ments, Union City, USA). Chipster software version 3.3 (http://
chipster.csc.fi/) was applied for loess normalisation and statistical
analysis.
Antigen microarray analysis
Full-length antigens were produced at the Københavns Universitet
NNF Center for Protein Research (UCPH) by expression in E. coli and
purified via a polyhistidine tag. To assure their purity, all proteins
were tested by SDS–PAGE prior to immobilisation. The list of the 54
antigens used in the analysis is shown in Supplementary Tab. 2. The
antigen microarrays were prepared as described for the antibody
microarrays. For spotting, however, a glycerol-based buffer (0.4 M
NaHPO4, pH 8.6, 10% glycerol, 0.01% (w/v) sarkosyl) was used. Each
antigen was spotted in triplicate within each of eight identical sub-
arrays placed on one microarray slide. Incubation with antibodies
was performed within 24 h after spotting. After an initial blocking
with the Candor Blocking Solution, 250 ml 33 nM recombinant
antibody was incubated on the arrays for 1 h. After washing, DY-
649-P1-labelled protein A/G (Biotrend, Cologne, Germany) was
added for detection to a concentration of 20 nM and incubated
for 30 min. Experiments were carried out in triplicate.
Affinity measurements by surface plasmon resonance (SPR)
A Sierra Sensors SPR-4 instrument (Sierra Sensors, Hamburg,
Germany) was used to acquire binding kinetics of selected scFv-
Fc:antigen pairs. Antigens were immobilised covalently to a flat
amine sensor chip to a level of 350 RU (protein CHFR) or 300 RU
(GRIP2). Interaction analysis was performed by injecting several
concentrations of the corresponding scFv-Fc antibody diluted in
PBS buffer at a flow rate of 30 ml/min. After each injection the
surface was regenerated using 10 mM glycine (pH 1.9) for 30 s. All
measurements were performed at 258C. Non-specific binding,
monitored on a blank flow cell, was subtracted from the SPR
signals. Rate constants were determined using the SPR-4 analysis
software (Sierra Sensors) assuming a 1:1 Langmuir binding model.
Immunohistochemistry (IHC)
For immunohistochemistry experiments, frozen tissue sections
were produced. They were fixed with -208C cold acetone for576 www.elsevier.com/locate/nbt5 min. Peroxidases were quenched with a 3% (v/v) H2O2 solution
in methanol. Slides and tissue sections were first blocked with
avidin (Dako, Kyoto, Japan) for 10 min, second with biotin (Dako)
for 10 min and finally with Power Block (BioGenex, San Ramon,
USA) for 1 h. Recombinant antibodies were biotinylated with EZ-
Link NHS-PEG4-Biotin according to the manufacturer’s protocol,
diluted in antibody diluent (Dako S3022) to a concentration of 5–
10 mg/ml and incubated on the sections overnight at 48C. Prior to
the incubation with streptavidin peroxidase (Kirkegaard & Perry
Laboratories) for 30 min, slides were washed with Tris-buffer sup-
plemented with 0.05% Tween-20. The colour reaction was carried
out by incubation for 2 min with liquid DAB+ substrate (Dako) and
counterstaining by Mayer’s hematoxylin solution (Merck, Darm-
stadt, Germany). Images were captured using a Zeiss Cell Observer
Z1 equipped with an AxioCam (Zeiss, Jena, Germany).
Results
Comparative antibody microarray analysis
The binder set used in this pilot study consisted of phage display
selected single chain variable fragments (scFvs) isolated from
universal phage display libraries, which allow the high-through-
put selection of human antibody fragments. After initial selection
by panning against 134 proteins or peptides (Supplementary Tab.
1), a set of 456 scFvs was picked from the binding molecules. Each
scFv was fused to a human Fc-fragment in order to create scFv-Fc
fusion antibodies. This binder format can be used equivalent to
human IgGs [18,19]. In order to investigate which of the con-
structs should be studied in more detail, the scFv-Fc antibodies
were spotted onto microarrays and incubated with clinical samples
(Fig. 1a). Incubation was with fluorescently labelled protein lysates
obtained from pancreatic adenocarcinoma (PDAC) and healthy
pancreas tissues as well as resected bladder tumours from patients,
who subsequently had either suffered tumour recurrence within
five years of tumour resection or had no relapse. All samples had
been studied before [14; unpublished results] and were known to
exhibit expression differences for proteins other than those repre-
sented by the scFv-Fc fusion antibodies used here.
Sample labelling and incubation as well as data analysis were
performed according to well-established procedures [12,17]. Vol-
cano plots (Fig. 2) present the degree and significance of differen-
tial protein expression. In total, antibodies to 31 proteins
exhibited a potentially significant up- or down-regulation in PDAC
compared to normal tissues, and antibodies to 38 proteins showed
such changes when comparing non-recurrent and recurrent blad-
der cancer tissues. Since 9 proteins were shared by both analyses,
an overall total of 60 proteins was found to be potentially differ-
entially expressed in the initial analysis. For the other 84 of the 134
proteins for which antibodies had been isolated, no variation was
identified. This could be due either to the lack of any such differ-
ence in the studied protein samples or the absence of an antibody
of sufficient sensitivity or specificity. For the majority of the 60
proteins that yielded varying signals, there was only one antibody
that showed this variation, while the other binders that were
intended to bind to the same target did not produce such a result.
Four proteins – CHFR, ITCH, GORASP2 and GRIP2 – exhibited
significant variations on more than one of the antibodies that had
been produced against them (Fig. 2). The consistent results made it
likely that the relevant scFv-Fc antibodies actually bound to the
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FIGURE 1
Typical results of microarray analyses. (a) Overlay-image of the scFv-Fc antibody microarray incubated with protein samples from PDAC tissue (green signal) and
the common reference (red signal). Depending on the amount of protein binding to each spot in comparison to the common reference, colours vary from green,
via yellow and orange to red. (b)–(d) Images are shown of incubations on the antigen microarrays of antibodies DM380-JA70-F6 (b), DM319-JA37-E9 (c) and
DM319-JA37-B11 (d). Bound scFv-Fc antibody was detected with fluorescently labelled protein A/G. White spots indicate a signal that is too intense to be
presented in colour. Spot streaking is an experimental artefact introduced during drying the arrays with pressurised air.
FIGURE 2
Visualisation of the antibody microarray analysis results as volcano plots. (Left panel) Relative variation of protein abundance in lysates of normal pancreatic and
PDAC tissues, respectively. A negative log2 fold change indicates down-regulation, while a positive change indicates overexpression of proteins in PDAC tissue
compared to normal tissue. (Right panel) The same is shown for proteins in non-recurrent versus recurrent bladder cancer tissues. Dots of the same colour
represent antibodies which were meant to recognize the same antigen; the colour code is given. The names of some relevant antibodies are shown. The dotted
horizontal line represents a p-value of 0.05.
R
es
ea
rc
h
P
ap
ersame target and that this target was differentially expressed in the
investigated sample cohorts. These antibodies (Table 1) were
selected for further characterisation.
Quality control of selected antibodies
After their initial isolation from the recombinant library, all scFv-
Fc antibodies had been used for ELISAs, testing if they recognizedthe antigen by which they were selected in the panning process.
However, these tests only determined if an antibody was able to
bind its target, but did not provide any information about speci-
ficity. In order to investigate the degree of cross-reactivity of the
candidate antibodies selected by the microarray analysis, they
were incubated individually on an antigen array onto which
full-length proteins had been spotted (Fig. 1b–d). In our pilotwww.elsevier.com/locate/nbt 577
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TABLE 1
List of antibodies selected for further characterisation. ‘+’ indicates the detection of a variation in the abundance of the assumed target
protein upon incubation of the antibody microarray with protein extracts isolated from clinical tissue samples.
Antibody name Antigen specificity (presumed) PDAC versus normal Bladder cancer recurrent versus non-recurrent
DM319-JA37-E9 CHFR
Uniprot ID: Q96EP1
+
DM319-JA37-G5 CHFR +
DM319-JA37-A9 CHFR +
DM319-JA37-B11 CHFR +
DM319-JA37-H7 CHFR +
DM319-JA37-D4 CHFR +
DM379-JA69-F11 GORASP2
Uniprot ID: Q9H8Y8
+
DM379-JA69-C9 GORASP2 +
DM379-JA69-G7 GORASP2 +
DM379-JA69-H3 GORASP2 +
DM379-JA69-E4 GORASP2 +
DM380-JA70-F6 GRIP2
Uniprot ID: Q9C0E4
+
DM380-JA70-A8 GRIP2 +
DM380-JA70-G4 GRIP2
DM380-JA70-B1 GRIP2 +
DM382-JA72-B7 ITCH
Uniprot ID: Q96J02
+ +
DM382-JA72-H1 ITCH
R
esearch
P
ap
erscheme, 54 proteins were presented on the antigen array, includ-
ing CHFR, ITCH, GORASP2 and GRIP2 (Supplementary Tab. 2).
Only the anti-CHFR antibody DM319-JA37-G5 (Fig. 3a) and
the anti-GRIP2 antibodies DM380-JA70-F6 and -A8 (Fig. 4a) rec-
ognized their target proteins with good specificity. The other
candidates were either cross-reactive (anti-CHFR antibodies
DM319-JA37-A9, -B11 and-E9) or did not bind to the antigen arrayFIGURE 3
Quality control of anti-CHFR antibodies. (a) Binding intensities on the antigen array
immobilised control antibody. The desired target antigen is marked in red. For be
Supplementary Tab. 3. (b) SPR binding curves of two anti-CHFR scFv-Fc antibodi
antibody (DM319-JA37-G5) at different concentrations; from this, a KD of 82.2 nM
578 www.elsevier.com/locate/nbtat all (anti-GRIP2 antibody DM380-JA70-G4 as well as all anti-
ITCH and anti-GROASP2 antibodies). The cross-reactive anti-
CHRF antibodies produced very similar binding patterns, also
recognizing the proteins DPOLL, OSTP1, OTUB1 and PRDM8,
but with varying intensities (Fig. 3a). For confirmation that
ITCH and GROASP2 did not interact with their antibodies, the
proteins were labelled fluorescently and individually incubated ons are shown. Signal intensities were normalised to the value achieved with an
tter visualisation, no error bars are shown. However, the data is available as
es are shown. (c) SPR binding curves are presented of the best performing
 was calculated.
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FIGURE 4
Quality control of anti-GRP2 antibodies. (a) Binding intensities on the antigen array are shown. Signal intensities were normalised to that of an immobilised control
antibody. The desired target antigen is marked in red. (b) SPR binding curves of three anti-GRIP2 scFv-Fc antibodies are shown. (c) SPR binding curves are
presented of the best performing antibody at different concentrations; from this, a KD of 6.5 nM was calculated.
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erantibody microarrays. In this inverse system too, there was no
binding to the respective antibodies (data not shown), which was
surprising as they had exhibited binding in ELISA tests previously.
To qualify the array-based results further, the affinities of the
anti-CHFR and anti-GRIP2 antibodies were measured quantitative-
ly with SPR. For comparison to the antigen array data, the antigens
were immobilised and the antibodies were added in different
concentrations. Anti-CHFR antibodies DM319-JA37-G5 (specific)
and DM319-JA37-E9 (cross-reactive) showed comparable binding
kinetics with moderate dissociation rates (Fig. 3b). Assuming a 1:1
Langmuir binding model, a KD of 82.2 nM could be calculated for
anti-CHFR antibody DM319-JA37-G5 (Fig. 3c). For the anti-GRIP2
antibodies (Fig. 4), there was strong binding of the specific binderFIGURE 5
Immunohistochemistry analysis of GRIP2 abundance in pancreatic tissues. Tissues is
healthy pancreatic tissue (normal) were stained with two antibodies. The antibod
pancreas.DM380-JA70-F6, which was also characterised by its slow dissoci-
ation rate, whereas for the antibodies DM380-JA70-A8 (specific)
and DM380-JA70-G4 (cross-reacting) binding was significantly
weaker. A KD of 6.5 nM was calculated for DM380-JA70-F6.
Confirmation of GRIP2 overexpression by immunohistochemistry
Some of the antibodies that had yielded apparently interesting
data in the microarray analysis could be confirmed by the quality
control experiments as binders of good specificity and affinity. In
turn, we used one of these good performers for validating the
differential protein abundance in the tumour samples observed in
the microarray analysis. To this end, immunohistochemistry was
carried out on frozen tissue sections (Fig. 5). Besides confirmingolated from patients with PDAC or chronic pancreatitis and from donors with
y DM380-JA70-F6 clearly showed a higher abundance of GRIP2 in diseased
www.elsevier.com/locate/nbt 579
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erthe biological variation seen in the microarray assay, the immu-
nohistochemistry assay allowed simultaneous testing of the binder
performance. Analysing pancreatic tissue sections with the specific
and high-affinity anti-GRIP2 antibody DM380-JA70-F6 confirmed
that GRIP2 was highly abundant in PDAC and chronic pancreatitis
compared to normal tissue. As expected, antibody DM380-JA70-
G4 produced inconclusive results.
Discussion
Although only performed on a small-scale, these pilot experiments
demonstrated the feasibility of screening, by means of antibody
microarrays, a preselected antibody library containing binders of
unknown quality for the isolation of useful antibodies, without
testing the performance parameters of every single candidate
beforehand. Simultaneously, utilising representative samples,
the process specifically selected antibodies that could be informa-
tive for a given application, such as the discrimination of pancre-
atic tumour from healthy tissue. Actually, there could well be more
‘good’ antibodies in the set of 456 molecules, useful for analyses
other than that of pancreatic and bladder tissues. The strategy is
most suited for a targeted binder selection process. The array
format permits flexibility with respect to the number of molecules
that could be studied. This number and the degree of selectivity of
the microarray assay can be adapted to both the actual needs and
the capacity for the subsequent, much more laborious binder
characterisation. Similarly, at the other end, the stringency of
the pre-selection process, through panning the original binder
library against the protein(s) of interest, can be tailored, depending
on the capacity of the array analysis.
Our analysis also demonstrated, unsurprisingly, that further
characterisation of the selected antibodies is essential; the anti-
body microarray analysis on its own is clearly insufficient when
dealing with molecules of unknown quality. Although there were
several antibodies that indicated abundance variations of proteins
ITCH and GROASP2, for instance, this result could not be con-
firmed during the subsequent antibody characterisation. It is likely
that the relevant antibodies bind to other proteins exhibiting
reproducible abundance variation. Neither when antibodies were
applied to the antigen array nor in the reverse experiment, when
the individual proteins were incubated on the antibody micro-
arrays, could specific binding be detected. In our pilot scheme,
only a small antigen array was used for identification of binding
specificity. The use of more comprehensive antigen microarrays580 www.elsevier.com/locate/nbtwould lead to a much better proof of the accurate binding of an
antibody to the intended target or the identification of any cross-
binding activity. In vitro production of proteins, and in particular
an in situ synthesis directly on the microarray surface [20–22]
permits the production of such complex analysis platforms.
The objective of our study was a demonstration of the utility of
the microarray-based selection process. During the course of this,
disease related differences in protein abundance were identified
and related antibodies of nanomolar affinity were isolated. How-
ever, the biological information gained from this is too prelimi-
nary to draw any conclusions on the value of GRIP2 or CHFR for
diagnosis, for instance. Firstly, the sample number was too small.
Secondly, for a comprehensive analysis, further controls would be
essential, such as samples from chronically inflamed pancreatic
tissue. Nevertheless, even in the very limited setting of the pilot
scheme, we succeeded in isolating antibodies that could well be
useful for biologically or biomedically motivated studies. Anti-
body DM380-JA70-F6, for example, is the first monoclonal anti-
body against GRIP2 according to the Antibodypedia data
repository (version 9 of June 2015; http://www.antibodypedia.
com) with information on 1 768 896 antibodies.
In conclusion, an efficient strategy was established that com-
bines the identification of protein variations of informative value
with the selection of related antibodies from a set of uncharac-
terised molecules derived from human antibody gene libraries.
Only after the application of relevant protein samples to the
antibody microarray are binders of potential interest characterised
further, so as to isolate appropriately performing antibodies for
further utilisation. This limits the task of antibody characterisation
– a bottleneck in current antibody production – to antibodies that
are informative in a particular biological context of interest.
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